bladder%20cancer
BLADDER CANCER

Bladder cancer is a heterogenous neoplasm that ranges from non-life-threatening, low-grade, superficial papillary lesions to high-grade invasive tumors that often metastasizes at the presentation.

It is the most common cancer involving the urinary system and it is the 11th most commonly diagnosed in the world.

Microscopic or gross painless hematuria is the most common presenting complaint.

Introduction

  • Bladder cancer is an uncontrollable growth of cancer cells in the hollow organs of the pelvis which is the bladder
  • Most common cancer involving the urinary system & it is the 11th most commonly diagnosed in the world
    • It is the 6th common cancer in US & 7th in UK
    • It is the 10th most common cancer in men in Singapore
  • The predominant histologic type of bladder cancer is the urothelial (transitional cell) carcinoma
  • It is 3-4 times prevalent in men than in women
    • But women present w/ more advanced disease & have worse survival

Signs and Symptoms

Symptoms

  • Microscopic or gross painless hematuria is the most common presenting complaint
  • Urinary frequency from irritation or a reduced bladder capacity can also develop
  • Dysuria & urgency are other complaints
  • Less commonly, a urinary tract infection is the presenting symptom
  • Upper tract obstruction or pain may occur in more advanced tumors

Risk Factors

Risk factors

  • Active & passive tobacco smoking is the most important risk factor for bladder cancer
    • Tobacco smoke contains aromatic amines & polycyclic aromatic hydrocarbons that are renally excreted
  • Occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons & chlorinated hydrocarbons is the second most important risk factor for bladder cancer
    • Occurs mainly in industrial plants processing paint, dye, metal & petroleum products
  • Increasing age
    • Mean age of diagnosis is 65 yrs
  • Exposure to ionizing radiation is connected w/ increased risk
    • There is an increased risk of developing bladder cancer in patients undergoing external-beam radiotherapy, brachytherapy or a combination
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Saras Ramiya, 6 days ago
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.